shot-button
Ganesh Chaturthi Ganesh Chaturthi
Home > News > India News > Article > Pfizer withdraws emergency use request for its COVID 19 vaccine in India

Pfizer withdraws emergency use request for its COVID-19 vaccine in India

Updated on: 06 February,2021 08:49 AM IST  |  New Delhi
PTI |

Pfizer was the first pharmaceutical firm to seek an emergency use authorisation from the DCGI for its COVID-19 vaccine in the country, after it secured such clearance in the UK and Bahrain

Pfizer withdraws emergency use request for its COVID-19 vaccine in India

Vials with COVID-19 Vaccine stickers attached and syringes with the logo of US pharmaceutical company Pfizer. Pic/AFP

Pharma major Pfizer on Friday said it has decided to withdraw its application for Emergency Use Authorisation (EUA) of its COVID-19 vaccine in India.


Pfizer was the first pharmaceutical firm to seek an emergency use authorisation from the Drugs Controller General of India (DCGI) for its COVID-19 vaccine in the country, after it secured such clearance in the UK and Bahrain.



"In pursuance of the Emergency Use Authorisation of its COVID-19 vaccine, Pfizer participated in the Subject Expert Committee meeting of the Drug Regulatory Authority of India on February 3. Based on the deliberations at the meeting and our understanding of additional information that the regulator may need, the company has decided to withdraw its application at this time," a company spokesperson said in a statement.


Pfizer will continue to engage with the authority and resubmit its approval request with additional information as it becomes available in the near future, the statement said.

"Pfizer remains committed to making its vaccine available for use by the Government in India and to pursuing the requisite pathway for emergency use authorisation that enables the availability of this vaccine for any future deployment," the spokesperson said.

Pfizer in its application submitted to the drug regulator in December 2020, had sought permission to import the vaccine for sale and distribution in India, besides waiver of clinical trials on Indian population in accordance with the special provisions under the New Drugs and Clinical Trials Rules, 2019, official sources had said. 

This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever

"Exciting news! Mid-day is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest news!" Click here!


Mid-Day Web Stories

Mid-Day Web Stories

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK